Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma
In light of the ongoing clinical development of KRAS G12D-specific inhibitors, we sought to investigate the clinicopathologic, co-occurring genomic features and outcomes of patients with KRAS G12D-mutant lung adenocarcinoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Hang Cao, Zelin Ma, Qingyuan Huang, Han Han, Yuan Li, Yang Zhang, Haiquan Chen Tags: Original Research Source Type: research
FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib.
Dear editor (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Nyere Gibson, Mathieu Larroquette, Charlotte Domblides, Felix Lefort, Amaury Daste Tags: Letter to the Editor Source Type: research
Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas
Uncertainty persists regarding clinical and treatment variations crucial to consider when comparing high human papillomavirus (HPV)-prevalence oropharyngeal squamous cell carcinoma (OPSCC) cohorts for accurate patient stratification and replicability of clinical trials across different geographical areas. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Amanda-Louise Fenger Carlander, Simone Kloch Bendtsen, Jacob H Rasmussen, Kathrine Kronberg Jakobsen, Martin Garset-Zamani, Christian Gr ønhøj, Jeppe Friborg, Katherine Hutcheson, Faye M. Johnson, Clifton D Fuller, Amy C Moreno, Toyin Babarinde, Neil D Tags: Original Research Source Type: research
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – a phase II randomised trial
The NIPU-trial investigates the effect of adding the telomerase vaccine UV1 to treatment with ipilimumab and nivolumab for patients with pleural mesothelioma (PM). (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K Nowak, Wee L Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Hellan Tags: Clinical Trial Source Type: research
Propranolol monotherapy in angiosarcoma - A window-of-opportunity study (PropAngio)
Angiosarcoma is a rare and aggressive cancer of the endothelial cells. Propranolol, a non-selective β-blocker, was able to initiate apoptosis in angiosarcoma cell lines and its anti-tumor activity has been described in several case reports. The aim of this trial was to prospectively evaluate the anti-tumor activity of propranolol monotherapy in patients with angiosarcoma before proceeding to stan dard of care treatment. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Alaa Embaby, Kimberley M. Heinhuis, Nikki S. IJzerman, Anne Miek Koenen, Stephanie van der Kleij, Ingrid Hofland, Hester van Boven, Joyce Sanders, Winette T.A. van der Graaf, Rick L. Haas, Alwin D.R. Huitema, Winan J. van Houdt, Neeltje Steeghs Tags: Original Research Source Type: research
A Meta-Analysis of Efficacy and Safety Data from Head-to-Head First-Line Trials of Epidermal Growth Factor Receptor Inhibitors versus Bevacizumab in Adult Patients with RAS Wild-Type Metastatic Colorectal Cancer by Sidedness
The first-line treatment choice of EGFRIs plus doublet chemotherapy vs. bevacizumab plus doublet chemotherapy remains a topic of interest for patients with left-sided RAS WT mCRC. We conducted a systematic literature review and meta-analysis of clinical trial data published between 2015 and 2024. We evaluated the relative efficacy and safety of first-line EGFRIs plus doublet chemotherapy (FOLFIRI or FOLFOX) vs. bevacizumab plus doublet chemotherapy for patients with RAS WT left-sided mCRC, as well as in all- and right-sided tumors. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Takayuki Yoshino, Naushin Hooda, Diana Younan, Kei Muro, Kohei Shitara, Volker Heinemann, Bert Howard O ’neil, Fernando Rivera Herrero, Marc Peeters, Junpei Soeda, Mina Suh, Heidi Reichert, Khalid Mezzi, Jon Fryzek, Victoria Chia, Marko Rehn, Sebastian Tags: Review Source Type: research
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combinations in first-line setting showed limited advantage compared to TT only. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Douglas B. Johnson, Ren áta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Tags: Original Research Source Type: research
Disease-free survival as a surrogate for overall survival in HR+/HER2 − early breast cancer: a correlation analysis
Overall survival (OS) is a universally accepted measure of clinical benefit; however, prolonged follow-up is needed to observe sufficient events. Disease-free survival (DFS) has been widely adopted as a primary endpoint for early breast cancer (EBC) trials, as follow-up is comparatively shorter. Here, we present an analysis evaluating DFS as a surrogate for OS for adjuvant treatment of hormone receptor –positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) EBC. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Michael Untch, David P érol, Erica L. Mayer, Javier Cortes, Arnd Nusch, David Cameron, Carlos Barrios, Thomas Delea, Andrii Danyliv, Namita Mishra, Rhea Gupta, Purnima Pathak, Peter A. Fasching Tags: Original Research Source Type: research
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD). However, decentralized solutions to test for HRD in clinical routine are scarce. The goal of this study was to retrospectively validate on tumor samples from the PAOLA-1 trial, the decentralized SeqOne assay, which relies on shallow Whole Genome Sequencing (sWGS) to capture genomic instability and targeted sequencing to determine BRCA status. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Romain Boidot, Michael G.B. Blum, Marie-Pierre Wissler, C éline Gottin, Jiri Ruzicka, Sandy Chevrier, Tiffany M. Delhomme, Jérome Audoux, Adrien Jeanniard, Pierre-Alexandre Just, Philipp Harter, Sandro Pignata, Antonio González-Martin, Christian Marth, Source Type: research
Survival trends for patients diagnosed with cutaneous malignant melanoma in the Nordic countries 1990-2016: The NORDCAN Survival Studies
The survival in patients diagnosed with cutaneous malignant melanoma (CMM) has improved in the Nordic countries in the last decades. It is of interest to know if these improvements are observed in all ages and for both women and men. (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 1, 2024 Category: Cancer & Oncology Authors: Frida Lundberg, Helgi Birgisson, Gerda Engholm, El ínborg J Ólafsdóttir, Lina Steinrud Mørch, Tom Børge Johannesen, David Pettersson, Mats Lambe, Karri Seppä, Paul C Lambert, Anna L V Johansson, Lisbet Rosenkrantz Hölmich, Therese M-L Andersson Tags: Original Research Source Type: research
Venetoclax plus Cytarabine and Azacitidine in Relapsed/Refractory AML: An Open-Label, Single-arm, Phase 2 Study.
The outcome of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains extremely poor. Venetoclax (VEN)-based regimens have shown promise in treating R/R AML. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 29, 2024 Category: Cancer & Oncology Authors: Liangshun You, Yi Liu, Wenyuan Mai, Wanzhuo Xie, De Zhou, Liping Mao, Lili Chen, Xinping Zhou, Liya Ma, Xiaolong Zheng, Juying Wei, Yinjun Lou, Xingnong Ye, Hongyan Tong, Jie Jin, Haitao Meng Tags: Original Research Source Type: research
Reconciling the Discrepancies in Randomized Data of Combining Immunotherapy and Radiation Therapy: Not all Radiotherapy is Created Equal
It remains highly unclear and debatable whether combining radiotherapy (RT) and immune checkpoint blocker (ICB) therapy yields improved outcomes compared to either modality alone. Whereas some randomized data have shown improved outcomes, others have not. As a result of these conflicting data, it is essential to reconcile differences in the data and postulate reasons thereof. This work seeks to address these discrepancies, and uses the lessons learned from both positive and negative trials, including the most cutting-edge data available, in order to guide future clinical trial design and clarify the ideal/expected role of ...
Source: European Journal of Cancer - February 28, 2024 Category: Cancer & Oncology Authors: Joe Y. Chang, Vivek Verma, Ralph R. Weichselbaum Tags: Current Perspective Source Type: research
The European Network for Sinonasal Cancer Research (EUSICA) – a pan-European initiative targeting a group of orphan tumours
Sinonasal cancers are a group of rare cancers which arise from the nasal cavities and paranasal sinuses and comprise of a wide spectrum of histologically distinct disease entities.[1] Diagnosis can be very challenging and treatment options are still very limited with some of these tumours having very dire clinical outcomes, e.g. sinonasal melanoma with a one- and five-year recurrence-free and overall survival of 61% and 22%, and 78% and 38%, respectively, similar to SNEC, SNUC, NUT and SMARCB1-deficient sinonasal carcinoma. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 21, 2024 Category: Cancer & Oncology Authors: Mario Hermsen, Paolo Bossi, David Capper, Jason Fleming, Johannes Haybaeck, Eva Martinez Balibrea, Sandra Nuyts, Alena Skalova, David Thomson, Annalisa Trama, Mario Turri-Zanoni, Benjamin Verillaud, Robbie Woods, Christian von Buchwald, Matt Lechner Tags: Editorial Source Type: research
Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: a retrospective study
This study investigated thyroid dysfunction with immune checkpoint inhibitors (ICIs) in terms of proportions affected, risk factors, thyroid sequelae, and overall survival (OS). (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 21, 2024 Category: Cancer & Oncology Authors: Oliver John Kennedy, Nadia Ali, Rebecca Lee, Phillip Monaghan, Safwaan Adam, Tim Cooksley, Paul Lorigan Tags: Original Research Source Type: research
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
This study aimed to (1) confirm efficacy of CBP501/cisplatin/nivolumab for metast atic PDAC observed in a previous phase 1 study, (2) identify combinations that yield 35% 3-month progression-free survival rate (3MPFS) and (3) define the contribution of CBP501 to the effects of combination therapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - February 21, 2024 Category: Cancer & Oncology Authors: T. Enzler, A. Nguyen, J. Misleh, V.J. Cline, M. Johns, N. Shumway, S. Paulson, R. Siegel, T. Larson, W. Messersmith, D. Richards, J. Chaves, E. Pierce, M. Zalupski, V. Sahai, D. Orr, S.A. Ruste, A. Haun, T. Kawabe Tags: Original Research Source Type: research
